Siegfried AG Reports Growth and Confirms Outlook for 2026

In the first half of 2026, Siegfried AG demonstrated growth across key financial metrics. The company's net sales reached CHF 633 million, a year-on-year increase of 4.8% in local currencies. Core EBITDA rose to CHF 142 million, improving its margin to 22.4%. This growth was driven by strong demand for development and manufacturing services, alongside strategic acquisitions.

Siegfried completed the acquisition of three drug substance sites in the US and Australia on May 1, enhancing its US market presence and operational capacity. This acquisition is anticipated to add around USD 100 million in net sales for 2026.

The company also advanced its EVOLVE+ strategy, focusing on operational excellence and sustainable value creation through targeted M&A activities. Siegfried maintains a positive outlook, projecting high-single-digit sales growth and a core EBITDA margin above 23% for the full year 2026.